引用本文: 符雨嫣,王昊德,孙辉,等.二代测序法用于非小细胞肺癌突变基因检测的经济学评价[J].中国卫生经济,2023,42(10):55-59.[点击复制] Fu Yuyan,Wang Haode,Sun Hui,et al.Economic Evaluation on the Next-Generation Sequencing for the Detection of Mutant Genes in Non-Small Cell Lung Cancer[J].CHINESE HEALTH ECONOMICS,2023,42(10):55-59.[点击复制]
【打印本页】 查看/发表评论 关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 187次   下载 148 本文二维码信息
码上扫一扫!
二代测序法用于非小细胞肺癌突变基因检测的经济学评价
符雨嫣,王昊德,孙辉,金春林,王海银
0
(上海市卫生和健康发展研究中心 (上海市医学科学技术情报研究所) 上海 201199)
摘要:
目的:分析与传统基因检测技术相比,二代测序法用于非小细胞肺癌突变基因检测的经济性。方法:对国际二代测序法用于非小细胞肺癌的经济学评价进行系统综述。从卫生体系视角出发,构建决策树模型,测算二代测序法 (8基因突变联合检测) 对比荧光实时定量PCR法 (3基因突变联合检测) 的成本-效果,并进行敏感性分析。结果:纳入4篇研究,其中2篇研究认为与传统基因检测技术相比,二代测序法用于非小细胞肺癌的突变基因检测具有一定的经济性,但仍需要结合具体情况进一步研究。模型研究结果表明,对比荧光实时定量PCR法 (3基因突变联合检测),采用二代测序法 (8基因突变联合检测),非小细胞肺癌患者多存活1年所需要增加的诊断成本为97 501.18元,以3倍人均GDP为阈值时,具有成本-效果。结论:二代测序法用于非小细胞肺癌突变基因检测具有一定经济性,但未来仍需要更新数据和结果。
关键词:  二代测序法  非小细胞肺癌  伴随诊断  经济学评价
DOI:
投稿时间:2023-07-27
基金项目:
Economic Evaluation on the Next-Generation Sequencing for the Detection of Mutant Genes in Non-Small Cell Lung Cancer
Fu Yuyan,Wang Haode,Sun Hui,Jin Chunlin,Wang Haiyin
(Shanghai Health Development Research Center(Shanghai Medical Science Technology Information Insti?tution), Shanghai, 201199 , China)
Abstract:
Objective: To analyze the economy of next-generation sequencing (NGS) for non-small cell lung cancer mutation gene detection compared with traditional gene detection technology. Methods: First, a systematic review was conducted on the eco- nomic evaluation of international NGS methods for non-small cell lung cancer. Secondly, from the perspective of the health system, the research builds a decision tree model to calculate incremental cost-effectiveness of the NGS method (joint detection of 8-gene mu- tations) versus the fluorescent real-time quantitative PCR (qPCR) method (joint detection of 3-gene mutations). Results: 4 studies were included, of which 2 studies believed that compared with traditional gene detection technology, NGS method for mutation gene detection of non-small cell lung cancer is economical, but still needs to be combined further research on the domestic situation. The results of the model study show that, compared with the qPCR, the NGS brings additional diagnostic cost for patients with non-small cell lung cancer to survive for 1 year is 97 501.18 yuan. It has cost-effectiveness when the threshold value is 3 times per capita GDP. Conclusion: The NGS method is economical for the detection of mutant genes in non-small cell lung cancer, but the data and results still need to be updated in the future.
Key words:  next-generation sequencing  non-small cell lung cancer  companion diagnosis  economic evaluation

用微信扫一扫

用微信扫一扫